loading
Precedente Chiudi:
$16.94
Aprire:
$16.9
Volume 24 ore:
47,809
Relative Volume:
0.47
Capitalizzazione di mercato:
$422.65M
Reddito:
$26.00M
Utile/perdita netta:
$-219.71M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-51.37M
1 W Prestazione:
-1.29%
1M Prestazione:
-25.50%
6M Prestazione:
-31.71%
1 anno Prestazione:
-51.72%
Intervallo 1D:
Value
$16.60
$17.68
Intervallo di 1 settimana:
Value
$16.36
$19.85
Portata 52W:
Value
$11.66
$42.60

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
Nome
Cartesian Therapeutics Inc
Name
Telefono
301-348-8698
Name
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Name
Dipendente
38
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
RNAC's Discussions on Twitter

Confronta RNAC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
RNAC 16.88 422.65M 26.00M -219.71M -51.37M 0.00
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.40 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 593.04 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.04 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.32 24.89B 3.30B -501.07M 1.03B 11.54

Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie

pulisher
07:09 AM

Cartesian Therapeutics to Present Updated Data from Phase - GlobeNewswire

07:09 AM
pulisher
05:23 AM

Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics - Simply Wall St

05:23 AM
pulisher
Nov 19, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Shares Gap UpWhat's Next? - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock By Investing.com - Investing.com Nigeria

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics director Timothy Springer buys $7.37M in stock - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian therapeutics CTO Metin Kurtoglu sells shares worth $1.44 million - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics' chief medical officer sells shares worth $907,532 - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cartesian Therapeutics executive sells $875,042 in stock - Investing.com

Nov 18, 2024
pulisher
Nov 17, 2024

Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 17, 2024
pulisher
Nov 14, 2024

Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Cartesian Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 13, 2024
pulisher
Nov 12, 2024

HC Wainwright Cuts Cartesian Therapeutics (NASDAQ:RNAC) Price Target to $41.00 - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Cartesian Therapeutics: Uncertainty Remains (NASDAQ:RNAC) - Seeking Alpha

Nov 10, 2024
pulisher
Nov 09, 2024

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Cartesian Therapeutics Inc (RNAC) Reports Q3 2024 EPS of $(1.13), Revenue of $387K, Missing Analyst Estimates - GuruFocus.com

Nov 09, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Cartesian Therapeutics Awards New Employee Stock Options at $19.11 Per Share | RNAC | RNAC Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 07, 2024

Cartesian Therapeutics Inc. (RNAC) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 05, 2024

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Cartesian's Novel mRNA CAR-T Therapy Data Selected for Major ASH Conference Spotlight | RNAC Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus Price Target from Analysts - Defense World

Nov 04, 2024
pulisher
Nov 01, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 01, 2024
pulisher
Oct 26, 2024

Insiders of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) must be disappointed as stock fell 10% after recent purchases - Simply Wall St

Oct 26, 2024
pulisher
Oct 18, 2024

Bullish Cartesian Therapeutics Insiders Loaded Up On US$5.18m Of Stock - Yahoo Finance

Oct 18, 2024
pulisher
Oct 16, 2024

Multiple Myeloma Pipeline Insights and Analysis 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, AbbVie, Pfizer, Cartesian Therapeutics, Rapa Therapeutics - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - StockTitan

Oct 15, 2024
pulisher
Oct 13, 2024

Insider Buying Slows, but Not for These 7 Buyers - 24/7 Wall St.

Oct 13, 2024
pulisher
Oct 11, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Position Reduced by Renaissance Technologies LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

30,038 Shares in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Purchased by Marshall Wace LLP - MarketBeat

Oct 09, 2024
pulisher
Oct 06, 2024

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? - MSN

Oct 06, 2024
pulisher
Oct 05, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock By Investing.com - Investing.com South Africa

Oct 05, 2024
pulisher
Oct 04, 2024

Timothy A. Springer Acquires 80,301 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Acquires 5,514 Shares of Stock - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian therapeutics director Timothy Springer buys $4.29m in stock - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc [NASDAQ: RNAC] Sees Increase in Stock Value - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Cartesian Therapeutics Inc (RNAC) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 04, 2024
pulisher
Oct 04, 2024

Emcore Corp. [EMKR] Records 50-Day SMA of $1.18 - Knox Daily

Oct 04, 2024
pulisher
Oct 03, 2024

Point72 DIFC Ltd Invests $47,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 03, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Takes Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Oct 01, 2024

Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):